No Data
No Data
DBS Maintains AptarGroup(ATR.US) With Buy Rating, Cuts Target Price to $175
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), BeiGene (ONC) and AptarGroup (ATR)
Some Confidence Is Lacking In AptarGroup, Inc.'s (NYSE:ATR) P/E
Caps and Closures Markets Report 2024-2030, Featuring Berry Global, Amcor, Silgan, Crown, AptarGroup, Berlin Packaging, Guala, CSI, Tekni-Plex, Tetra Pak, ALPLA Werke Alwin Lehner, WestRock
AptarGroup Price Target Cut to $190.00/Share From $200.00 by Raymond James
Express News | Raymond James Reiterates Outperform on AptarGroup, Lowers Price Target to $190